RECURRENT GRADE 3 FOLLICULAR LYMPHOMA

This early-stage trial is testing a new combination of three drugs for people whose non-Hodgkin lymphoma has come back after previous treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and…

This early-phase study is testing the safety and best dose of a personalized cell therapy for patients with aggressive B-cell lymphomas that have returned or are high-risk. The treatment involves collecting a patient's own immune cells (T cells), genetically modifying them in a l…

This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…

This study tested a daily pill called ibrutinib in 41 patients with follicular lymphoma, a type of blood cancer, that had returned or stopped responding to previous treatments. The main goal was to see how well the drug could shrink the cancer and control the disease. Researchers…

This study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…